- Profile
- prev
- next
General
-
Founders & Team
Manuel Serrano, Marc Ramis Castelltort
-
Year Founded
2017
-
Company type
Private company
-
Funding stage
Seed
-
Total funding ($M)
0.5
-
Investors
Life Biosciences
Technical Details
-
Aging Target
Cellular senescence
-
Product modality
fibrotic disease
-
Clinical stage
Pre-clinical
About
Senolytic Therapeutics (STX) is a discovery-stage biotech developing novel medicines that target senescent cells.
STX´s discovery programs serve as launchpads for developing innovative drugs that improve and extend healthy lives by the elimination of senescent cells.
Our Mission: to generate value through innovation built into our discovery programs.
Our portfolio is focused on developing new medicines to treat age-related disorders such as fibrositic diseases.
Founded in 2017, Senolytic Therapeutics SL is based in Barcelona, Spain.
OUR SCIENCE
Senescence was first described more than 50 years ago, and was initially conceptualized as a damaged, cellular state that occurs in vitro. Later evidence demonstrated that senescence also occurs in animals and humans and increases with age.
Today, senescence is not just considered a passive association with aging, but rather a causal driver of many age-related processes and pathologies. Senescent cell elimination in various disease models in vivo has demonstrated efficacy, validating it as a promising therapeutic approach.
SENESCENT CELLS
Senescent cells are damaged cells that have undergone a proliferative arrest and resist death, which has led to their description as ¨zombie cells¨ in pop science culture. Senescent cells secrete a cadre of pro-inflammatory and pro-fibrotic factors which drive a host of different age-related disorders. Targeting senescent cells with drugs that preferentially eliminate them (¨senolytic therapies¨) is promising strategy to treat and cure many diseases, in particular those associated with fibrosis.
OUR FINDINGS
Our academic founder, Dr. Manuel Serrano, has made key discoveries in the field of senescence relating to the identification of cell cycle regulator p16, the concept of oncogene-induced senescence, the existence of senescent cells in vivo, and the role of senescence in reprogramming.
The science at STX is based on our unique ability to design and develop strategies that selectively target and eliminate damaged cells from tissues where they drive disease progression.